Cara Therapeutics/CARA

$0.64

2.57%
-
1D1W1MYTD1YMAX

About Cara Therapeutics

Cara Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of novel therapeutics to treat serious medical conditions, including pruritus. The Company’s KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Its novel compound, difelikefalin, is a highly selective, primarily peripherally acting kappa opioid receptor (KOR) agonist. The Company is developing an oral formulation of difelikefalin and has Phase III programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease (NDD-CKD), and atopic dermatitis (AD). In addition, the Company has initiated a Phase II/III program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica (NP).
Ticker
CARA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Christopher Posner
Employees
106
Headquarters
Stamford, United States

CARA Metrics

BasicAdvanced
$34.12M
Market cap
-
P/E ratio
-$2.16
EPS
0.59
Beta
-
Dividend rate

What the Analysts think about CARA

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 7 analysts.
714.06% upside
High $11.00
Low $1.00
$0.64
Current price
$5.21
Average price target

CARA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-583.33% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$4.8M
-30.43%
Net income
$-28M
-10.83%
Profit margin
-583.33%
28.18%

CARA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.56
-$0.49
-$0.58
-$0.52
-
Expected
-$0.32
-$0.52
-$0.54
-$0.52
-$0.41
Surprise
75%
-6.03%
7.74%
0%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Cara Therapeutics stock

Buy or sell Cara Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing